First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study

Androgen Deprivation ◽

First Line ◽

Gland Carcinoma ◽

Positive Recurrent

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

Case Medical Research ◽

10.31525/ct1-nct03942653 ◽

2019 ◽

Author(s):

Keyword(s):

Salivary Gland ◽

Androgen Receptor ◽

Androgen Deprivation ◽

Advanced Stage ◽

A randomised phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in patients with recurrent and/or metastatic, Androgen Receptor (AR) expressing, Salivary Gland Cancer (SGC)

10.26226/morressier.596cd2b8d462b80292387c64 ◽

2017 ◽

Author(s):

Carmela Caballero

Keyword(s):

Salivary Gland ◽

Androgen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Androgen Deprivation ◽

Salivary Gland Cancer ◽

Efficacy And Safety

Advanced salivary gland carcinoma expressing androgen receptor and HER2: targeted therapies first?

Annals of Oncology ◽

10.1016/j.annonc.2020.03.302 ◽

2020 ◽

Vol 31 (7) ◽

pp. 958-959

Author(s):

E. Quaquarini ◽

F. Sottotetti ◽

D. Presti

Keyword(s):

Salivary Gland ◽

Androgen Receptor ◽

Targeted Therapies ◽

Abstract CT137: Phase II study of trastuzumab and docetaxel therapy in patients with HER2-positive recurrent and/or metastatic salivary gland carcinoma

10.1158/1538-7445.am2019-ct137 ◽

2019 ◽

Author(s):

Ichiro Kinoshita ◽

Satoshi Kano ◽

Yasushi Shimizu ◽

Naomi Kiyota ◽

Yuichiro Tada ◽

...

Keyword(s):

Salivary Gland ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Gland Carcinoma ◽

Positive Recurrent

Posttreatment Response Assessment Using 18 F-FDG PET in Salivary Gland Carcinoma Patients Treated With Definitive Radiation Therapy—A Multicentric Retrospective Study

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.06.1415 ◽

2017 ◽

Vol 99 (2) ◽

pp. E340-E341

Author(s):

C.E. Hsieh ◽

C.H. Lee ◽

S.P. Hung ◽

K.H. Fan ◽

J.T.C. Chang ◽

...

Keyword(s):

Radiation Therapy ◽

Salivary Gland ◽

Retrospective Study ◽

Fdg Pet ◽

Response Assessment ◽

Combined androgen blockade in patients with advanced androgen receptor-positive salivary gland carcinoma: Exploratory biomarker analyses

Annals of Oncology ◽

10.1093/annonc/mdz252.058 ◽

2019 ◽

Vol 30 ◽

pp. v471-v472

Author(s):

C. Fushimi ◽

D. Kawakita ◽

H. Takahashi ◽

T. Nagao ◽

H. Hirai ◽

...

Keyword(s):

Salivary Gland ◽

Androgen Receptor ◽

Combined Androgen Blockade ◽

Gland Carcinoma ◽

Androgen Blockade

Abstract CT137: Phase II study of trastuzumab and docetaxel therapy in patients with HER2-positive recurrent and/or metastatic salivary gland carcinoma

10.1158/1538-7445.sabcs18-ct137 ◽

2019 ◽

Author(s):

Ichiro Kinoshita ◽

Satoshi Kano ◽

Yasushi Shimizu ◽

Naomi Kiyota ◽

Yuichiro Tada ◽

...

Keyword(s):

Salivary Gland ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Gland Carcinoma ◽

Positive Recurrent

A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma

Annals of Oncology ◽

10.1093/annonc/mdx771 ◽

2018 ◽

Vol 29 (4) ◽

pp. 979-984 ◽

Cited By ~ 43

Author(s):

C. Fushimi ◽

Y. Tada ◽

H. Takahashi ◽

T. Nagao ◽

H. Ojiri ◽

...

Keyword(s):

Salivary Gland ◽

Androgen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Combined Androgen Blockade ◽

Prospective Phase ◽

Gland Carcinoma ◽

Androgen Blockade

Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target

Journal of Oral Pathology and Medicine ◽

10.1111/jop.12741 ◽

2018 ◽

Vol 47 (7) ◽

pp. 691-695 ◽

Cited By ~ 7

Author(s):

Chit Cheng Yeoh ◽

Nedal Dabab ◽

Elyse Rigby ◽

Ritu Chhikara ◽

Iolia Akaev ◽

...

Keyword(s):

Salivary Gland ◽

Androgen Receptor ◽

Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps6099 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS6099-TPS6099

Author(s):

Laura Locati ◽

Carmela Aves Caballero ◽

Catherine Fortpied ◽

Federica Perrone ◽

Pasquale Quattrone ◽

...

Keyword(s):

Salivary Gland ◽

Androgen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Androgen Deprivation ◽

Salivary Gland Cancer ◽

Efficacy And Safety ◽

Randomized Phase Ii